<p>艾伯维公司（NYSE:ABBV - 获取免费报告）在周二的交易中股价下跌了 2.1%。该公司的股价最低曾达到 204.53 美元，最后交易价为 204.88 美元。在午盘交易中，共交易了 1,360,577 股，较平均交易量 5,250,727 股下降了 74%。该股票此前收盘价为 209.17 美元。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>艾伯维股票通过进入减肥市场提升投资组合</li>
</ul>
<p>几位股票分析师最近对 ABBV 股票发表了评论。富国银行将艾伯维的目标价从 210.00 美元上调至 240.00 美元，并在 3 月 5 日的研究报告中给予该公司 “超配” 评级。Erste Group Bank 在 3 月 17 日的研究报告中将艾伯维的股票评级提升至 “强力买入”。Piper Sandler Companies 在 12 月 17 日的研究报告中重申了 “超配” 评级，并对艾伯维的股票设定了 220.00 美元的目标价。BMO 资本市场在 2 月 3 日的研究报告中将艾伯维的目标价从 208.00 美元上调至 215.00 美元，并给予该股票 “跑赢大盘” 评级。最后，美国银行在 3 月 4 日的研究报告中将艾伯维的目标价从 200.00 美元上调至 223.00 美元，并给予该公司 “中性” 评级。五位研究分析师对该股票给予了持有评级，十七位给予了买入评级，三位给予了强力买入评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 211.45 美元。</p>
<p><strong>查看我们对 ABBV 的最新分析</strong></p>
<h2>艾伯维价格表现</h2>
<ul>
<li>4 个在通胀高企时表现良好的行业</li>
</ul>
<p>该股票的市值为 3528.5 亿美元，市盈率为 83.42，市盈增长比率为 1.62，贝塔值为 0.61。该公司的 50 日移动平均价格为 195.14 美元，200 日移动平均价格为 188.73 美元。公司的流动比率为 0.66，速动比率为 0.55，债务股本比率为 17.94。</p>
<p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 1 月 31 日发布了季度财报。该公司报告每股收益为 2.16 美元，低于市场共识预期的 2.98 美元，差额为 0.82 美元。艾伯维的股本回报率为 296.28%，净利润率为 7.59%。在去年同期，该公司每股收益为 2.79 美元。整体来看，卖方分析师预计艾伯维公司在当前财政年度的每股收益将达到 12.31 美元。</p>
<h2>艾伯维宣布分红</h2>
<ul>
<li>吉利德科学：该股票还有更多上涨空间的 4 个理由</li>
</ul>
<p>该公司最近还宣布了季度分红，将于 5 月 15 日支付。4 月 15 日的股东将获得 1.64 美元的分红。除息日为 4 月 15 日。这相当于年化 6.56 美元的分红，分红收益率为 3.28%。艾伯维的分红支付比率目前为 273.33%。</p>
<h2>艾伯维的内部交易</h2>
<p>在相关消息中，执行副总裁 Timothy J. Richmond 在 2 月 26 日的交易中出售了 29,917 股艾伯维股票。该股票以平均价格 202.90 美元出售，总价值为 6,070,159.30 美元。出售完成后，该执行副总裁现在直接持有公司 44,284 股，价值约为 8,985,223.60 美元。这笔交易代表其持股减少了 40.32%。该交易已在证券交易委员会的备案中披露，相关信息可通过 SEC 网站访问。此外，高级副总裁 Kevin K. Buckbee 在 2 月 26 日的交易中出售了 18,944 股公司股票。该股票以平均价格 203.41 美元出售，总交易额为 3,853,399.04 美元。交易完成后，该高级副总裁现在持有公司 11,496 股，价值为 2,338,401.36 美元。这代表其持股减少了 62.23%。该交易的披露信息可在此找到。在过去三个月中，内部人士共出售了 54,639 股公司股票，价值为 11,067,025 美元。内部人士持有公司股票的比例为 0.25%。</p>
<h2>机构投资者对艾伯维的看法</h2>
<p>一些对冲基金最近增加或减少了对该股票的持仓。M1 Capital Management LLC 在第四季度购买了艾伯维的新股份，价值为 229,000 美元。DSG Capital Advisors LLC 在第四季度购买了艾伯维的新股份，价值约为 3,213,000 美元。Chancellor Financial Group WB LP 在第四季度购买了艾伯维的新股份，价值约为 981,000 美元。Thoma Capital Management LLC 在第四季度购买了艾伯维的新股份，价值约为 551,000 美元。最后，Lansforsakringar Fondforvaltning AB publ 在第四季度购买了艾伯维的新股份，价值约为 104,347,000 美元。目前，70.23% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>艾伯维公司简介</h2>
<p>（获取免费报告）</p>
<p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性和肠道 Behçet 病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票，胜过艾伯维</li>
<li>什么是成长股及其投资</li>
<li>创新孵化器：企业家调查揭示最支持初创企业的城市</li>
<li>什么是债券市场假期？如何投资和交易</li>
<li>NVIDIA 内部人士抛售：这对市场意味着什么</li>
<li>做空：如何做空一只股票</li>
<li>太空股票触底：哪些股票最有可能反弹？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
<p>在考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前立即购买的股票……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>AbbVie Inc.（纽约证券交易所代码：ABBV）股价在交易中下跌 2.1%，至 204.88 美元，成交量显著下降。分析师的评级意见不一，富国银行将其目标价上调至 240.00 美元，BMO 资本市场则上调至 215.00 美元。AbbVie 报告每股收益为 2.16 美元，未达到预期，并宣布季度股息为 1.64 美元。内部人士的减持情况引起关注，管理层减少了持股比例。该股票的市值为 3528.5 亿美元，目前的股息收益率为 3.28%</p>

<p>AbbVie Inc. (NYSE:ABBV - Get Free Report) shares fell 2.1% during trading on Tuesday . The company traded as low as $204.53 and last traded at $204.88. 1,360,577 shares were traded during mid-day trading, a decline of 74% from the average session volume of 5,250,727 shares. The stock had previously closed at $209.17.</p>
<div class="lb-trans"><p>艾伯维公司（NYSE:ABBV - 获取免费报告）在周二的交易中股价下跌了 2.1%。该公司的股价最低曾达到 204.53 美元，最后交易价为 204.88 美元。在午盘交易中，共交易了 1,360,577 股，较平均交易量 5,250,727 股下降了 74%。该股票此前收盘价为 209.17 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li>
</ul>
<div class="lb-trans"><ul>
<li>艾伯维股票通过进入减肥市场提升投资组合</li>
</ul>
</div><p>Several equities analysts have recently commented on ABBV shares. Wells Fargo &amp; Company increased their price objective on AbbVie from $210.00 to $240.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, March 5th. Erste Group Bank raised shares of AbbVie to a &#34;strong-buy&#34; rating in a research note on Monday, March 17th. Piper Sandler Companies reaffirmed an &#34;overweight&#34; rating and issued a $220.00 price objective on shares of AbbVie in a research note on Tuesday, December 17th. BMO Capital Markets lifted their target price on shares of AbbVie from $208.00 to $215.00 and gave the stock an &#34;outperform&#34; rating in a research report on Monday, February 3rd. Finally, Bank of America upped their price target on shares of AbbVie from $200.00 to $223.00 and gave the company a &#34;neutral&#34; rating in a research report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $211.45.</p>
<div class="lb-trans"><p>几位股票分析师最近对 ABBV 股票发表了评论。富国银行将艾伯维的目标价从 210.00 美元上调至 240.00 美元，并在 3 月 5 日的研究报告中给予该公司 “超配” 评级。Erste Group Bank 在 3 月 17 日的研究报告中将艾伯维的股票评级提升至 “强力买入”。Piper Sandler Companies 在 12 月 17 日的研究报告中重申了 “超配” 评级，并对艾伯维的股票设定了 220.00 美元的目标价。BMO 资本市场在 2 月 3 日的研究报告中将艾伯维的目标价从 208.00 美元上调至 215.00 美元，并给予该股票 “跑赢大盘” 评级。最后，美国银行在 3 月 4 日的研究报告中将艾伯维的目标价从 200.00 美元上调至 223.00 美元，并给予该公司 “中性” 评级。五位研究分析师对该股票给予了持有评级，十七位给予了买入评级，三位给予了强力买入评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 211.45 美元。</p>
</div><p><strong>View Our Latest Analysis on ABBV</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ABBV 的最新分析</strong></p>
</div><h2>AbbVie Price Performance</h2>
<div class="lb-trans"><h2>艾伯维价格表现</h2>
</div><ul>
<li>4 Sectors That Thrive When Inflation Runs Hot</li>
</ul>
<div class="lb-trans"><ul>
<li>4 个在通胀高企时表现良好的行业</li>
</ul>
</div><p>The stock has a market cap of $352.85 billion, a P/E ratio of 83.42, a price-to-earnings-growth ratio of 1.62 and a beta of 0.61. The business's 50 day moving average price is $195.14 and its two-hundred day moving average price is $188.73. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94.</p>
<div class="lb-trans"><p>该股票的市值为 3528.5 亿美元，市盈率为 83.42，市盈增长比率为 1.62，贝塔值为 0.61。该公司的 50 日移动平均价格为 195.14 美元，200 日移动平均价格为 188.73 美元。公司的流动比率为 0.66，速动比率为 0.55，债务股本比率为 17.94。</p>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same period in the previous year, the firm earned $2.79 earnings per share. As a group, sell-side analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 1 月 31 日发布了季度财报。该公司报告每股收益为 2.16 美元，低于市场共识预期的 2.98 美元，差额为 0.82 美元。艾伯维的股本回报率为 296.28%，净利润率为 7.59%。在去年同期，该公司每股收益为 2.79 美元。整体来看，卖方分析师预计艾伯维公司在当前财政年度的每股收益将达到 12.31 美元。</p>
</div><h2>AbbVie Announces Dividend</h2>
<div class="lb-trans"><h2>艾伯维宣布分红</h2>
</div><ul>
<li>Gilead Sciences: 4 Reasons This Stock Has Much More To Rise</li>
</ul>
<div class="lb-trans"><ul>
<li>吉利德科学：该股票还有更多上涨空间的 4 个理由</li>
</ul>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a $1.64 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.28%. AbbVie's dividend payout ratio is currently 273.33%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度分红，将于 5 月 15 日支付。4 月 15 日的股东将获得 1.64 美元的分红。除息日为 4 月 15 日。这相当于年化 6.56 美元的分红，分红收益率为 3.28%。艾伯维的分红支付比率目前为 273.33%。</p>
</div><h2>Insider Transactions at AbbVie</h2>
<div class="lb-trans"><h2>艾伯维的内部交易</h2>
</div><p>In related news, EVP Timothy J. Richmond sold 29,917 shares of AbbVie stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total value of $6,070,159.30. Following the completion of the sale, the executive vice president now directly owns 44,284 shares in the company, valued at approximately $8,985,223.60. This trade represents a 40.32 % decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, SVP Kevin K. Buckbee sold 18,944 shares of the company's stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $203.41, for a total transaction of $3,853,399.04. Following the transaction, the senior vice president now owns 11,496 shares in the company, valued at $2,338,401.36. This represents a 62.23 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 54,639 shares of company stock valued at $11,067,025. Insiders own 0.25% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Timothy J. Richmond 在 2 月 26 日的交易中出售了 29,917 股艾伯维股票。该股票以平均价格 202.90 美元出售，总价值为 6,070,159.30 美元。出售完成后，该执行副总裁现在直接持有公司 44,284 股，价值约为 8,985,223.60 美元。这笔交易代表其持股减少了 40.32%。该交易已在证券交易委员会的备案中披露，相关信息可通过 SEC 网站访问。此外，高级副总裁 Kevin K. Buckbee 在 2 月 26 日的交易中出售了 18,944 股公司股票。该股票以平均价格 203.41 美元出售，总交易额为 3,853,399.04 美元。交易完成后，该高级副总裁现在持有公司 11,496 股，价值为 2,338,401.36 美元。这代表其持股减少了 62.23%。该交易的披露信息可在此找到。在过去三个月中，内部人士共出售了 54,639 股公司股票，价值为 11,067,025 美元。内部人士持有公司股票的比例为 0.25%。</p>
</div><h2>Institutional Investors Weigh In On AbbVie</h2>
<div class="lb-trans"><h2>机构投资者对艾伯维的看法</h2>
</div><p>A number of hedge funds have recently added to or reduced their stakes in the stock. M1 Capital Management LLC bought a new stake in shares of AbbVie in the fourth quarter worth $229,000. DSG Capital Advisors LLC bought a new stake in shares of AbbVie during the 4th quarter valued at about $3,213,000. Chancellor Financial Group WB LP purchased a new stake in shares of AbbVie during the 4th quarter valued at about $981,000. Thoma Capital Management LLC bought a new position in shares of AbbVie in the 4th quarter worth approximately $551,000. Finally, Lansforsakringar Fondforvaltning AB publ purchased a new position in shares of AbbVie in the fourth quarter worth approximately $104,347,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金最近增加或减少了对该股票的持仓。M1 Capital Management LLC 在第四季度购买了艾伯维的新股份，价值为 229,000 美元。DSG Capital Advisors LLC 在第四季度购买了艾伯维的新股份，价值约为 3,213,000 美元。Chancellor Financial Group WB LP 在第四季度购买了艾伯维的新股份，价值约为 981,000 美元。Thoma Capital Management LLC 在第四季度购买了艾伯维的新股份，价值约为 551,000 美元。最后，Lansforsakringar Fondforvaltning AB publ 在第四季度购买了艾伯维的新股份，价值约为 104,347,000 美元。目前，70.23% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>AbbVie Company Profile</h2>
<div class="lb-trans"><h2>艾伯维公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性和肠道 Behçet 病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>What Are Growth Stocks and Investing in Them</li>
<li>Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>NVIDIA Insiders Sell: This Is What It Means for the Market</li>
<li>Short Selling: How to Short a Stock</li>
<li>Space Stocks Bottoming: Which Are Positioned Best for a Bounce?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过艾伯维</li>
<li>什么是成长股及其投资</li>
<li>创新孵化器：企业家调查揭示最支持初创企业的城市</li>
<li>什么是债券市场假期？如何投资和交易</li>
<li>NVIDIA 内部人士抛售：这对市场意味着什么</li>
<li>做空：如何做空一只股票</li>
<li>太空股票触底：哪些股票最有可能反弹？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前立即购买的股票……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

艾伯维（NYSE:ABBV）股价下跌 2.1% - 事情是这样的